National Practice Patterns for Prenatal Monitoring in Gastroschisis: Gastroschisis Outcomes of Delivery (GOOD) Provider Survey.


Journal

Fetal diagnosis and therapy
ISSN: 1421-9964
Titre abrégé: Fetal Diagn Ther
Pays: Switzerland
ID NLM: 9107463

Informations de publication

Date de publication:
2019
Historique:
received: 11 12 2017
accepted: 06 02 2018
pubmed: 24 5 2018
medline: 12 9 2019
entrez: 24 5 2018
Statut: ppublish

Résumé

Gastroschisis is an abdominal wall defect with increasing incidence. Given the lack of surveillance guidelines among maternal-fetal medicine (MFM) specialists, this study describes current practices in gastroschisis management. An online survey was administered to MFM specialists from institutions affiliated with the North American Fetal Therapy Network (NAFTNet). Questions focused on surveillance timing, testing, findings that changed clinical management, and delivery plan. Responses were obtained from 29/29 (100%) NAFTNet centers, comprising 143/371 (39%) providers. The majority had a regimen for antenatal surveillance in patients with stable gastroschisis (94%; 134/141). Antenatal testing began at 32 weeks for 68% (89/131) of MFM specialists. The nonstress test (55%; 72/129), biophysical profile (50%; 63/126), and amniotic fluid index (64%; 84/131) were used weekly. Estimated fetal weight (EFW) was performed monthly by 79% (103/131) of providers. At 28 weeks, abnormal EFW (77%; 97/126) and Doppler ultrasound (78%; 99/127) most frequently altered management. In stable gastroschisis, 43% (60/140) of providers delivered at 37 weeks, and 29% (40/ 140) at 39 weeks. Gastroschisis management differs among NAFTNet centers, although the majority initiate surveillance at 32 weeks. Timing of delivery still requires consensus. Prospective studies are necessary to further optimize practice guidelines and patient care.

Sections du résumé

BACKGROUND BACKGROUND
Gastroschisis is an abdominal wall defect with increasing incidence. Given the lack of surveillance guidelines among maternal-fetal medicine (MFM) specialists, this study describes current practices in gastroschisis management.
MATERIALS AND METHODS METHODS
An online survey was administered to MFM specialists from institutions affiliated with the North American Fetal Therapy Network (NAFTNet). Questions focused on surveillance timing, testing, findings that changed clinical management, and delivery plan.
RESULTS RESULTS
Responses were obtained from 29/29 (100%) NAFTNet centers, comprising 143/371 (39%) providers. The majority had a regimen for antenatal surveillance in patients with stable gastroschisis (94%; 134/141). Antenatal testing began at 32 weeks for 68% (89/131) of MFM specialists. The nonstress test (55%; 72/129), biophysical profile (50%; 63/126), and amniotic fluid index (64%; 84/131) were used weekly. Estimated fetal weight (EFW) was performed monthly by 79% (103/131) of providers. At 28 weeks, abnormal EFW (77%; 97/126) and Doppler ultrasound (78%; 99/127) most frequently altered management. In stable gastroschisis, 43% (60/140) of providers delivered at 37 weeks, and 29% (40/ 140) at 39 weeks.
DISCUSSION CONCLUSIONS
Gastroschisis management differs among NAFTNet centers, although the majority initiate surveillance at 32 weeks. Timing of delivery still requires consensus. Prospective studies are necessary to further optimize practice guidelines and patient care.

Identifiants

pubmed: 29791899
pii: 000487541
doi: 10.1159/000487541
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

125-130

Informations de copyright

© 2018 S. Karger AG, Basel.

Auteurs

Ruchi Amin (R)

Pediatric Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USAramin520@gmail.com.

Aaron Domack (A)

Pediatric Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Joseph Bartoletti (J)

Pediatric Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Erika Peterson (E)

Maternal Fetal Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Britton Rink (B)

Maternal and Fetal Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.

Jennifer Bruggink (J)

Pediatric Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Melissa Christensen (M)

Pediatric Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Anthony Johnson (A)

Maternal and Fetal Medicine, University of Texas Health Sciences Center, Houston, Texas, USA.

William Polzin (W)

Maternal and Fetal Medicine, Cincinnati Children's Hospital, Cincinnati, Ohio, USA.

Amy J Wagner (AJ)

Pediatric Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH